The investment was made after Meytag obtained approval of Novosurge's R&D plan from the Office of the Chief Scientist's incubators committee against a government loan to Meytag. Meytag will own 35% of Novosurge after the investment.
Novosurge's robotic surgical device is used for surgical incisions through the sternum and to greatly improve the precision of these procedures. The company said, "Use of the structured sternum incision system is intended to increase the stability of the bone, greatly reduce the risk of post-surgical complications, and shorten recovery time."
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments